Gilead Sciences appoints Stacey Ma as EVP, Pharmaceutical Development and Manufacturing
Taiyin Yang, PhD, Executive Vice President, Pharmaceutical Development and Manufacturing to Retire After 29 Years at Gilead
Taiyin Yang, PhD, Executive Vice President, Pharmaceutical Development and Manufacturing to Retire After 29 Years at Gilead
Facility features LED lighting, solar panels, automation and innovative temperature-controlled systems to maximize efficiency and minimize environmental impact
Besides enhancing workflow operations by connecting scientists with their lab instruments and data, digitalization holds the potential to acceleratee long-term business growth
120+ members of multi-disciplinary medical team are trained to provide seamless, outcome driven trauma and emergency care
Auld is a seasoned Financial Executive with over 30 years of relevant experience
This agreement is in addition to the $92 million filling line expansion announced in November 2021
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Motrin Oral Suspension, 100 mg/5 mL, of McNeil Consumer Healthcare (McNeil)
OS-SiA is the industry’s first AI-enabled digital scanner that will provide real-time predictive analysis and actionable insights
Subscribe To Our Newsletter & Stay Updated